The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
NanoString will initially draw $60 million at close, which will net it approximately $8 million after repaying its existing debt with the investment firm.
The new building will serve as a hub for ARUP's lab campus, handling processing of new specimen as well as high-volume testing.
The company raised $3.2 million in seed financing, which will go toward development of its platform and deployment of its flagship technology called VIPER.
The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.
The firm's Cell-CT platform takes photos of an epithelial cell spinning through a microfluidic tube to produce a 3D image to find defects linked to lung cancer.
The firm is developing tests combining biomarkers and other clinical measures to diagnose and monitor patients and identify those at risk of long-term effects.
ARMADA began as a consortium of eight US organizations but has increased to 50 institutions in 20 countries and signed on actor Bill Pullman as a spokesman.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.